00761nas a2200277   4500000000100000008004100001100001300042700001100055700001300066700001500079700001700094700001600111700001100127700001400138700001300152700001500165700001200180700001500192700001300207700001300220700001300233700001000246700001400256245020600270490000700476       2018                            d1 aCooper M1 aToto R1 aZinman B1 aPerkovic V1 aRosenstock J1 aAlexander J1 aMarx N1 aPencina M1 aWanner C1 aBaanstra D1 aPfarr E1 aMattheus M1 aBroedl U1 aWoerle H1 aGeorge J1 avon E1 aMcGuire D00aRationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): A randomized, double-blind, placebo-control0 v17